Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.
Crinetics Pharmaceuticals (CRNX) is a clinical-stage biopharmaceutical company pioneering oral therapies for endocrine disorders and related tumors. This news hub provides investors and industry professionals with timely updates on clinical trial progress, regulatory milestones, and corporate developments.
Access official press releases, financial reports, and scientific updates related to CRNX's lead candidates: paltusotine for acromegaly/carcinoid syndrome and atumelnant targeting adrenal disorders. Our curated news collection enables efficient tracking of therapeutic innovations in rare diseases, partnership announcements, and market-moving events.
Content spans clinical data publications, FDA communications, executive leadership updates, and research collaborations. Bookmark this page for direct access to primary-source information about CRNX's novel small molecule therapies and their development pathways.
Crinetics Pharmaceuticals (CRNX) is advancing its clinical trials with key milestones expected in 2023. The Phase 3 PATHFNDR trials of paltusotine for acromegaly are on track for topline data readouts in 2H 2023, with plans to submit data for regulatory approval if successful. Additionally, a Phase 2 trial of paltusotine in carcinoid syndrome is anticipated to deliver topline data in 2H 2023. The company plans to initiate trials for CRN04894 targeting ACTH-dependent Cushing’s syndrome and congenital adrenal hyperplasia in Q1 2023, as part of its strategy to build a comprehensive endocrine-focused pipeline.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the granting of non-qualified stock options to twelve new non-executive employees on December 10, 2022. Under the 2021 Employment Inducement Incentive Award Plan, a total of 356,300 shares were awarded with an exercise price of $16.26, reflecting the fair market value at the time of the grant. These options will vest over four years, encouraging employee retention. This move aligns with Nasdaq Listing Rule 5635(c)(4), which allows for equity awards to induce employment for new hires.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced an update on CRN04777, an oral somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism. Following an Investigational New Drug application submitted to the FDA, the proposed Phase 2 clinical study was placed on hold pending further information from the agency. Previous Phase 1 trials indicated CRN04777 was well tolerated in adults, with no serious side effects reported.
SAN DIEGO, Nov. 22, 2022 – Crinetics Pharmaceuticals (Nasdaq: CRNX) will participate in the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2022. The company will host a fireside chat on November 30, 2022, at 1:00 PM (ET), moderated by Josh Schimmer, Research Analyst at Evercore ISI. The presentation will be accessible via the Evercore ISI platform and will be available for replay for 90 days. Interested parties can arrange virtual 1x1 meetings with Crinetics management through their bank or conference representative.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the completion of enrollment in the Phase 3 PATHFNDR-1 trial for acromegaly, with topline data expected in Q3 2023. The company reported a net loss of $41.9 million for Q3 2022, a significant increase from $27.9 million in Q3 2021. Revenues totaled $0.5 million, primarily from a licensing agreement. Research and development expenses rose to $32 million. Crinetics also received an Innovation Passport from the UK MHRA for CRN04777, which could expedite its market entry.
On November 10, 2022, Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the grant of non-qualified stock option awards totaling 200,000 shares under its 2021 Employment Inducement Incentive Award Plan to four new non-executive employees. This grant, effective immediately, aligns with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $18.59 per share, equivalent to the fair market value on the grant date, and will vest over four years, contingent on continued employment.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the completion of enrollment for its Phase 3 PATHFNDR-1 study evaluating paltusotine in acromegaly patients. A total of 58 participants, exceeding the planned 52, were enrolled. Topline results are anticipated in Q3 2023. The study aims to assess the safety and efficacy of once-daily oral paltusotine compared to placebo. If successful, data will be submitted to regulatory authorities for approval for all acromegaly patients requiring treatment. The PATHFNDR-2 study remains ongoing, with results expected in Q4 2023.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced on October 10, 2022, that it granted stock options for 237,600 shares to eleven new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The options, exercisable at $16.89 per share, vest over four years, beginning with 25% on the one-year anniversary and the remainder monthly thereafter, contingent on continued employment. This plan adheres to Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to drive the company's focus on developing therapeutics for rare endocrine diseases.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced that the UK MHRA granted CRN04777 an 'Innovation Passport' for treating congenital hyperinsulinism. This designation allows access to the Innovative Licensing and Access Pathway (ILAP), aimed at expediting market entry for critical therapies. Congenital hyperinsulinism is a serious condition affecting infants, necessitating continuous glucose management. The ILAP enhances coordination with the MHRA and allows for quicker Marketing Authorization Application reviews. CRN04777, an oral SST5 selective agonist, demonstrated promising results in preclinical studies.
Crinetics Pharmaceuticals (CRNX) appointed Dr. Dana Pizzuti as chief development officer, bringing over 30 years of pharmaceutical experience in clinical development and regulatory affairs. Dr. Pizzuti previously held key roles at companies like Ascendis Pharma, where she led successful regulatory applications. She will oversee the advancement of Crinetics’ drug pipeline, including Phase 3 studies for paltusotine targeting acromegaly. This management change aims to strengthen Crinetics’ capacity to navigate regulatory processes and enhance its multi-asset pipeline.
